Preferred Label : zanubrutinib;
MeSH synonym : (7S)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide;
UNII : AG9MHG098Z;
Origin ID : C000629551;
UMLS CUI : C4683810;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3534476/fr/brukinsa-zanubrutinib-lymphome-folliculaire-lf
2024
false
false
false
France
insurance, health, reimbursement
treatment outcome
antineoplastic agents
zanubrutinib
antineoplastic combined chemotherapy protocols
obinutuzumab
evaluation of the transparency committee
zanubrutinib
lymphoma, follicular
---
https://ansm.sante.fr/tableau-acces-derogatoire/brukinsa-80-mg-gelules
2023
false
false
false
France
French
drug information
zanubrutinib
---
https://www.has-sante.fr/jcms/p_3476374/fr/brukinsa-zanubrutinib-macroglobulinemie-de-waldenstrom-mw
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Refractory Waldenstrom Macroglobulinemia
adult
zanubrutinib
administration, oral
hematologic agents
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
zanubrutinib
waldenstrom macroglobulinemia
---
https://www.has-sante.fr/jcms/p_3461141/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Loss of Chromosome 17p
TP53 Gene Mutation
adult
del(17p) Negative
TP53 Gene Mutation Negative
Refractory Chronic Lymphocytic Leukemia
administration, oral
zanubrutinib
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
zanubrutinib
leukemia, lymphocytic, chronic, B-Cell
---
https://www.has-sante.fr/jcms/p_3434604/fr/brukinsa-zanubrutinib-leucemie-lymphoide-chronique
2023
false
false
false
France
evaluation of the transparency committee
zanubrutinib
leukemia, lymphoid
leukaemia
zanubrutinib
Brukinsa
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
chronic lymphocytic leukemia
---
https://www.has-sante.fr/jcms/p_3454298/fr/brukinsa-zanubrutinib-lymphome-de-la-zone-marginale-lzm
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
zanubrutinib
zanubrutinib
administration, oral
adult
Recurrent Marginal Zone Lymphoma
antineoplastic agents
protein kinase inhibitors
---
https://www.has-sante.fr/jcms/p_3330884/fr/brukinsa-zanubrutinib-macroglobulinemie-de-waldenstrom
2022
false
false
false
France
evaluation of the transparency committee
waldenstrom macroglobulinemia
Brukinsa
zanubrutinib
Waldenström macroglobulinemia
zanubrutinib
registries
---
https://cadth.ca/fr/zanubrutinib
2021
false
false
false
Canada
French
English
insurance, health, reimbursement
drug information
Zanubrutinib
piperidines
pyrazoles
pyrimidines
waldenstrom macroglobulinemia
zanubrutinib
---
https://www.cadth.ca/fr/zanubrutinib-0
2021
false
false
false
Canada
French
English
insurance, health, reimbursement
drug evaluation
zanubrutinib
antineoplastic agents
lymphoma, mantle-cell
zanubrutinib
protein kinase inhibitors
adult
---